Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Cash from Operations: 2022-2024

Historic Cash from Operations for Addex Therapeutics (ADXN) over the last 3 years, with Dec 2024 value amounting to $6,107.1 billion.

  • Addex Therapeutics' Cash from Operations fell 26.49% to $6,107.1 billion in Q4 2024 from the same period last year, while for Dec 2024 it was -$67.9 billion, marking a year-over-year decrease of 201.52%. This contributed to the annual value of -$6.1 million for FY2024, which is 31.36% up from last year.
  • Latest data reveals that Addex Therapeutics reported Cash from Operations of $6,107.1 billion as of Q4 2024, which was up 198.90% from -$6,175.0 billion recorded in Q3 2024.
  • Addex Therapeutics' Cash from Operations' 5-year high stood at $8,307.9 billion during Q4 2023, with a 5-year trough of -$6,175.0 billion in Q3 2024.
  • Its 3-year average for Cash from Operations is -$85.9 million, with a median of -$3.4 million in 2022.
  • Data for Addex Therapeutics' Cash from Operations shows a peak YoY increase of 260,550,017.06% (in 2023) and a maximum YoY decrease of 94,015,817.11% (in 2023) over the last 5 years.
  • Over the past 3 years, Addex Therapeutics' Cash from Operations (Quarterly) stood at -$3.2 million in 2022, then skyrocketed by 260,550,017.06% to $8,307.9 billion in 2023, then declined by 26.49% to $6,107.1 billion in 2024.
  • Its last three reported values are $6,107.1 billion in Q4 2024, -$6,175.0 billion for Q3 2024, and -$3.6 million during Q2 2024.